Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Baumstein
S Block
J Whitworth

Showing results (581-590 of 601) with videos related to

Pageof 61
Sort By:
Human Molecular Genetics|April 11, 2013
Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channelMine S Cicek, Devin C Koestler, Brooke L Fridley, et al.
Journal for Immunotherapy of Cancer|March 15, 2022
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancerStephanie Lheureux, Daniela E Matei, Panagiotis A Konstantinopoulos, et al.
Nature Communications|February 16, 2024
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trialTina J Hieken, Garth D Nelson, Thomas J Flotte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2024
A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic MalignanciesEleftheria Kalogera, Wendy K Nevala, Heidi D Finnes, et al.
Nature Communications|March 14, 2025
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trialJacob J Orme, Henan Zhang, Prashanth Lingamaneni, et al.
Development (Cambridge, England)|October 9, 2024
Advancing stem cell technologies for conservation of wildlife biodiversityAshlee M Hutchinson, Ruth Appeltant, Tom Burdon, et al.
Cancer|November 10, 2024
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastasesDanielle K DePalo, Michelle M Dugan, Syeda Mahrukh Hussnain Naqvi, et al.
JCO Oncology Advances|April 1, 2026
Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark AnalysisLuigi A De Vitis, Melissa C Larson, Hunter J Atkinson, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2022
The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort studyCarl-Jacob Holmberg, Lars Ny, Tina J Hieken, et al.
Annals of Surgical Oncology|January 28, 2022
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Pageof 61

Showing results (581-590 of 601) with videos related to

Sort By:
Pageof 61
Human Molecular Genetics|April 11, 2013
Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channelMine S Cicek, Devin C Koestler, Brooke L Fridley, et al.
Journal for Immunotherapy of Cancer|March 15, 2022
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancerStephanie Lheureux, Daniela E Matei, Panagiotis A Konstantinopoulos, et al.
Nature Communications|February 16, 2024
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trialTina J Hieken, Garth D Nelson, Thomas J Flotte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2024
A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic MalignanciesEleftheria Kalogera, Wendy K Nevala, Heidi D Finnes, et al.
Nature Communications|March 14, 2025
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trialJacob J Orme, Henan Zhang, Prashanth Lingamaneni, et al.
Development (Cambridge, England)|October 9, 2024
Advancing stem cell technologies for conservation of wildlife biodiversityAshlee M Hutchinson, Ruth Appeltant, Tom Burdon, et al.
Cancer|November 10, 2024
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastasesDanielle K DePalo, Michelle M Dugan, Syeda Mahrukh Hussnain Naqvi, et al.
JCO Oncology Advances|April 1, 2026
Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark AnalysisLuigi A De Vitis, Melissa C Larson, Hunter J Atkinson, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2022
The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort studyCarl-Jacob Holmberg, Lars Ny, Tina J Hieken, et al.
Annals of Surgical Oncology|January 28, 2022
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Pageof 61